Phase IV Services & Products

11. A Chief Medical Officer's Perspective On Selecting A CRO 5/14/2012

    Santosh Vetticaden, Ph.D., M.D. is a drug development professional with over 20 years of experience spanning large pharma and biotech across multiple therapeutic areas. He has been involved in trials from Phase I-Phase IV and has been extensively involved in the design, planning, and implementation of global trials. By Rob Wright, Chief Editor, Life Science Leader magazine

12. Industry Insights From PAREXEL Chief Operating Officer Dr. Goldberg 4/10/2012
    Over the past several years, the biopharmaceutical industry has been preparing for many blockbusters to come off patent. Facing the difficulty of replacing that revenue stream the industry’s focus in the emerging niche-buster era has centered on how to make R&D more efficient, including in the management of R&D dollars. By Rob Wright, Chief Editor, Life Science Leader magazine
13. Industry Trends From A Twenty Year CRO Veteran 4/5/2012
    Steve Powell is the EVP for PRA, a global clinical research organization (CRO) providing service through all phases of clinical development, which has supported 3,100 clinical trials in more than 80 countries. By Rob Wright, Chief Editor, Life Science Leader magazine
14. Insights And A Peek Into The Future For PRO & ePRO 12/12/2011

    PHT Corporation’s U.S. PRO & ePRO Congress, held in Boston Nov. 9-10, shared electronic patient reported outcome (ePRO) adoption growth numbers, discussions of new regulatory guidance, actionable information that can ease site and study subject burden from ePRO, PRO and ePRO in post-approval, and lingering reasons for sponsor reluctance to adopt ePRO. By Sara Gambrill